Physician profile
Michael G Ho
NPI 1013171834
$10,552.76
in general payments reported to CMS, 2019-2025
38 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $1,477 · 2021: $2,494 · 2022: $1,274 · 2023: $1,590 · 2024: $1,916 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,984.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,627.47 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $1,418.86 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Abbvie INC. | $1,269.56 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,180.83 | 2021-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $692.19 | 2023-2025 | Ultomiris, Soliris |
| Amgen INC. | $462.64 | 2020-2023 | Aimovig |
| Lilly USA, LLC | $440.99 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Emd Serono, INC. | $334.01 | 2019-2024 | Mavenclad |
| Biogen, INC. | $319.05 | 2021-2024 | Vumerity, Leqembi, Tysabri |
| Lundbeck LLC | $287.17 | 2021-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $246.28 | 2022 | |
| Sunovion Pharmaceuticals INC. | $233.43 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $202.43 | 2023-2024 | Aptiom |
| Sk Life Science, INC. | $201.33 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $193.58 | 2020-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $165.83 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $160.16 | 2019-2025 | |
| Abbott Laboratories | $141.20 | 2022 | |
| Acadia Pharmaceuticals INC | $110.25 | 2024-2025 | Nuplazid |
| Acorda Therapeutics, INC | $108.94 | 2019-2024 | Ampyra, Inbrija |
| Greenwich Biosciences, INC. | $106.27 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $89.99 | 2021 | |
| Eisai INC. | $82.87 | 2019-2020 | |
| Allergan, INC. | $74.33 | 2020 | |
| Amneal Pharmaceuticals LLC | $66.53 | 2022-2025 | Crexont |
| Neurelis, INC. | $65.50 | 2021-2025 | Valtoco |
| Genentech USA, INC. | $32.81 | 2024 | Ocrevus |
| Integra Lifesciences Corporation | $32.10 | 2020 | |
| Bausch Health US, LLC | $24.92 | 2019 | |
| Supernus Pharmaceuticals, INC. | $23.25 | 2019 | |
| Genzyme Corporation | $23.22 | 2020 | |
| Avanir Pharmaceuticals, INC. | $23.19 | 2020 | |
| Jazz Pharmaceuticals INC. | $21.90 | 2022 | |
| Aquestive Therapeutics, INC. | $20.55 | 2022 | |
| Impel Pharmaceuticals INC. | $20.23 | 2023 | Trudhesa |
| Horizon Therapeutics Plc | $20.18 | 2021 | |
| Assertio Therapeutics, INC. | $14.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.